Across TCGA pan-cancer cohorts, DEFB131C RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated DEFB131C data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DEFB131C RNA is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB131C expression acts as an unfavorable survival marker.
STAD are the cancer types where DEFB131C RNA most reproducibly stratifies survival.